Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about ALLERGAN PLC
08/14ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
AQ
08/14BIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
08/10ALLERGAN : and Editas Medicine Announce Exercise of Options to Jointly Develop C..
AQ
08/08ALLERGAN : Report of unscheduled material events or corporate event
PU
08/08ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
PR
08/03U.S. tax cuts prompt rethink by some 'inverted' companies
RE
08/02ALLERGAN : Announces Third Quarter 2018 Cash Dividend of $0.72 per Ordinary Shar..
AQ
07/31Novartis Gets EU Nod for First-Of-Its-Kind Migraine Drug
DJ
07/30ALLERGAN : Announces Third Quarter 2018 Cash Dividend of $0.72 Per Ordinary Shar..
PR
07/30Anti-Aging Products And Services Market By Key Participants Allergan Plc, Alm..
AQ
07/28Anti-Aging Products And Services Market By Key Participants Allergan Plc, Alm..
AQ
07/26ALLERGAN : 2Q Earnings Snapshot
AQ
07/26ALLERGAN : Reports Strong Second Quarter 2018 Results Including GAAP Net Revenue..
PR
07/26ALLERGAN : Statement of changes in beneficial ownership of securities
PU
07/23ALLERGAN : Receives FDA Fast Track Designation for AGN-241751 for the Treatment ..
PR
More most relevant news
All news about ALLERGAN PLC
08/14ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
AQ
08/14BIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
08/10ALLERGAN : and Editas Medicine Announce Exercise of Options to Jointly Develop C..
AQ
08/09ALLERGAN : Trademark Application for "PRESBYSOL" Filed
AQ
08/09ALLERGAN : An Application for the Trademark "BIOCELL" Has Been Filed by Allergan
AQ
08/09ALLERGAN : Reports Outline Pharmaceutical Science Study Results from Allergan (F..
AQ
08/08ALLERGAN : Report of unscheduled material events or corporate event
PU
08/08ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
08/08ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
PR
08/03U.S. tax cuts prompt rethink by some 'inverted' companies
RE
More news
Sector news : Pharmaceuticals - NEC
08/14MONSANTO ROUNDUP APPEAL HAS UPHILL C : legal experts
RE
08/14CSL : Annual Net Profit Rises, Slightly Beats Guidance
DJ
08/14Billionaire Investor David Einhorn Hit In Monsanto Ruling --Update
DJ
08/14DAVID EINHORN : Billionaire Investor David Einhorn Hit In Monsanto Ruling
DJ
08/14TSX advances as oil prices boost energy stocks
RE
08/14NOVARTIS : recruits new compliance head from Siemens after ethics stumbles
RE
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/14Eton Pharmaceuticals Files For U.S. IPO 
08/14Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update 
08/13Broyhill Asset Management Mid-Year Letter 2018 
08/11STOCKS TO WATCH : Any Privacy For Tesla? 
08/10Are Drug Stocks Starved Of Capital? 
08/10FDA OKs birth control app 
Latest Tweets
08/14$WPI ALERT: New Allergan plc SEC Filing From our Stock News Alerts App 
08/14Paulson & Co. adds Comcast, exits McDermott $MITL $AKRX $CMCSA $FOXA $LHO..
4
08/14Top 3 -- #1 Pfizer Oncology loses its CMO to Allergan as cancer exec Charles .. 
08/14Endo Has A Huge Opportunity — And Allergan May Want A Piece Of It
1
08/14$AGN taps Pfizer vet Hugh-Jones as CMO
1
More tweets
Qtime:460
Financials ($)
Sales 2018 15 535 M
EBIT 2018 7 412 M
Net income 2018 -1 106 M
Debt 2018 23 084 M
Yield 2018 1,50%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,51x
EV / Sales 2019 5,28x
Capitalization 62 458 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 208 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC12.48%62 458
JOHNSON & JOHNSON-7.31%350 770
PFIZER12.40%239 423
NOVARTIS-1.07%209 596
ROCHE HOLDING LTD.-2.84%207 317
MERCK AND COMPANY18.11%175 715